Drug intelligence / Profile preview

jingyin gubiao

Development stage: Unknown
Lead developer: Shuguang Hospital
Administration: Oral

Overview

Jingyin Gubiao is a Traditional Chinese Medicine (TCM) formula developed as a granule preparation by Shuguang Hospital, affiliated with the Shanghai University of Traditional Chinese Medicine. It is primarily utilized for the treatment and prevention of COVID-19, including the management of asymptomatic infections and the recovery of post-discharge patients. The formula is designed to "strengthen the exterior" (Gubiao) and clear pathogenic heat and toxins, aiming to enhance the body's immune response against viral respiratory infections. It has been evaluated in multiple clinical trials in China to determine its impact on viral clearance and symptom resolution.

Brand names: Jingyin Gubiao granules
Other names: Jingyin Gubiao formulaJingYinGuBiao Formula荆银固表颗粒Jingyin Gubiao granule

Beyond the preview

Go deeper on jingyin gubiao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on jingyin gubiao.

Explore the full profile